Kadcyla Injection, Powder, Lyophilized, For Solution
Product Images NDC 50242-088

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Kadcyla (NDC 50242-088). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Genentech, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Chemical Structure (Kadcyla 01)

Chemical structure diagram of ado-trastuzumab emtansine, showing the DM1 cytotoxic agent linked to the trastuzumab monoclonal antibody via an MCC linker. The diagram labels DM1 and MCC linker components and indicates an average drug-to-antibody ratio (n) of approximately 3.5.*

FDA Label Image

Figure 1 (Kadcyla 02)

A Kaplan-Meier curve chart showing Progression-Free Survival Rate over Time (months) comparing Lap+Cap (lapatinib plus capecitabine) and Ado-trastuzumab emtansine treatments. The chart includes the number at risk over time for both groups and notes statistical methods for hazard ratio and p-value estimation.*

FDA Label Image

Figure 2 (Kadcyla 03)

A Kaplan-Meier survival curve chart showing the proportion surviving over a duration of 36 months. It compares two groups: Lap+Cap (lapatanib and capecitabine) with 496 subjects and Ado-trastuzumab emtansine with 495 subjects. The x-axis represents duration of survival in months and the y-axis shows proportion surviving. The chart includes a legend and a risk table showing number at risk over time for both groups.*

FDA Label Image

Figure 3 (Kadcyla 04)

A Kaplan-Meier survival curve comparing the proportion of event-free patients over time in months between two groups: Trastuzumab and ado-trastuzumab emtansine, each with 743 patients. The chart includes censored data points and a table showing the number of patients at risk at various time intervals up to 60 months.*

FDA Label Image

Principal Display Panel (100 mg Vial Carton)

Label for Kadcyla (ado-trastuzumab emtansine) injection, powder, lyophilized, for solution. The label indicates 100 mg per vial strength, intended for intravenous infusion only. It is a single-dose vial with instructions to discard unused portions and to keep refrigerated. Manufactured by Genentech, Inc.*

FDA Label Image

Principal Display Panel (160 mg Vial Carton)

KADCYLA (ado-trastuzumab emtansine) injection, 160 mg per vial, for intravenous infusion. The label indicates it is a single-dose vial requiring reconstitution and dilution prior to administration. It should be kept refrigerated. Manufactured by Genentech, Inc.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.